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BRIEF REPORT
Endothelial Progenitor Cell Phenotype and Function Are Impaired in
Childhood-Onset Systemic Lupus Erythematosus
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Becky Thompson,1 Lawrence Ng,2 Deborah Levy,2 Earl Silverman,2 and Mariana J. Kaplan3
Objective. Systemic lupus erythematosus (SLE)
is characterized by increased cardiovascular risk in
adult-onset and childhood-onset SLE. Type I interfer-
ons (IFNs) appear to play a prominent role in prema-
ture vascular damage in adult-onset SLE, at least in
part, by inducing impairments in the phenotype and
function of endothelial progenitor cells (EPCs), thereby
hampering vascular repair. It is not clear whether EPC
dysfunction is present in childhood-onset SLE in asso-
ciation with a type I IFN signature.
Methods. The phenotype and numbers of EPCs
were quantified in patients with childhood-onset SLE,
patients with juvenile idiopathic arthritis (JIA), and
matched healthy control subjects. In a separate cohort
of patients with childhood-onset SLE, markers of sub-
clinical atherosclerosis and endothelial dysfunction
were quantified using standardized protocols and ana-
lyzed for associations with serum type I IFN activity.
Results. EPC numbers and function were signifi-
cantly decreased in patients with childhood-onset SLE
compared with patients with JIA and healthy control
subjects. Serum from patients with childhood-onset SLE
impaired differentiation of EPCs into mature endothelial
cells in healthy controls, and this effect was blocked by
inhibition of the type I IFN pathway. Type I IFN activity
in serum was not significantly associated with subclinical
atherosclerosis and endothelial function in patients with
childhood-onset SLE.
Conclusion. As in adult-onset SLE, childhood-
onset SLE is characterized by phenotypic and func-
tional EPC abnormalities, which are likely triggered by
type I IFNs. Although cross-sectional analysis revealed
no global association between type I IFN signatures and
vascular measures of subclinical atherosclerosis, longi-
tudinal assessments are needed to evaluate whether
progression of vascular damage in patients with
childhood-onset SLE is associated with type I IFNs, as
observed in patients with adult-onset SLE.
Cardiovascular (CV) morbidity and mortality are
increased in patients with systemic lupus erythematosus
(SLE) and cannot be explained using the Framingham
risk equation (1,2). Patients with childhood-onset SLE
have a greater disease burden due to a younger age at
onset and often present with more severe clinical manifes-
tations and major organ involvement (3). Subclinical ath-
erosclerosis has been reported in childhood-onset SLE,
with significant increases in carotid intima-media thick-
ness (CIMT) (4,5). Although treatment with atorvastatin
may decrease the progression of CIMT in a subset of
patients with childhood-onset SLE, it did not reduce the
overall atherosclerosis risk (6), indicating that other fac-
tors involved in the pathophysiology of endothelial dam-
age play a central role in vascular pathology.
We and other investigators have proposed that
type I interferons (IFNs) play an important role in the
pathogenesis of accelerated atherosclerosis in patients
with adult-onset SLE (7–9), through deleterious pleio-
tropic effects on the vasculature. Type I IFNs induce sig-
nificant impairment of the capacity of endothelial
progenitor cells (EPCs) to differentiate into mature
endothelial cells (ECs) and repair the vasculature (7,10).
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In murine models of lupus and atherosclerosis, type I
IFN blockade abrogates endothelial dysfunction, the
prothrombotic phenotype, plaque formation, and abnor-
mal vasculogenesis (11,12). We previously showed asso-
ciations between type I IFN activity in serum with
vascular dysfunction and enhanced subclinical carotid
and coronary atherosclerosis in patients with adult-onset
SLE (13). These observations suggest a crucial role for
these cytokines in initiating and perpetuating athero-
sclerotic lesions in patients with SLE.
A strong inverse correlation between CV risk fac-
tors and the number and function of circulating EPCs in
adults with various CV risk factors was previously
reported (7,10). Although little is known about EPCs
and their role in atherogenesis in children, there is evi-
dence that certain pediatric populations at risk of vascu-
lar disease have impaired EPC phenotype and function
that correlate with endothelial dysfunction (14,15).
We hypothesized that childhood-onset SLE is also
characterized by aberrant EPC phenotype and function
secondary to enhanced type I IFN activity. We posit that
these abnormalities may promote endothelial dysfunction
and accelerated vascular damage in children.We analyzed
EPC phenotype and function in patients with childhood-
onset SLE and the association with type I IFN activity.
We also assessed the association between type I IFN activ-
ity and vascular measures of early atherosclerosis.
PATIENTS AND METHODS
Subject recruitment. Age- and sex-matched healthy
control subjects and patients with childhood-onset SLE fulfill-
ing the American College of Rheumatology criteria (16) were
enrolled at the Hospital for Sick Children (HSC; 132 patients
and 170 healthy controls) and at the University of Michigan
(UM; 25 patients and 29 healthy controls). Children fulfilling
the International League Against Rheumatism criteria for
juvenile idiopathic arthritis (JIA; n5 21) (17) were enrolled at
UM. In the HSC cohort of patients with SLE, serum was
obtained for assessment of type I IFN activity, and subclinical
atherosclerosis and endothelial dysfunction were quantified by
CIMT using a GE Vivid 7 ultrasound system (GE Vingmed), a
12-MHz linear array transducer, and a Vascular Tools Carotid
Analyzer (Medical Imaging Applications LLC); by brachial
artery flow-mediated dilation (FMD), using the same ultra-
sound system and a Vascular Tools Brachial Analyzer (Medi-
cal Imaging Applications LLC); and by pulse wave velocity
(PWV), using a Millar SPC-301 high-fidelity micromanometer
and a SphygmoCor system (AtCor Medical). Vascular mea-
sures were compared with normative data acquired using the
same standardized protocols (4). Institutional review boards
approved the study, and all subjects provided written informed
consent.
EPC quantification. In the UM cohorts of healthy
control subjects, patients with SLE, and patients with JIA,
peripheral blood mononuclear cells (PBMCs) were obtained,
and EPCs were quantified by fluorescence-activated cell sort-
ing analysis as previously described (7,8,11–13), on a FACS-
Calibur flow cytometer (BD Biosciences). A total of 10,000
events were quantified, and the results were analyzed using
FlowJo software. EPCs were characterized as described by our
group (CD341CD1331CD42CD32CD562CD79b2).
Assessment of EC differentiation. PBMCs were plated
on fibronectin-coated plates (4 million cells/well; BD Bioscien-
ces) and cultured for 2 weeks in endothelial growth medium
with 20% fetal bovine serum (FBS) (Gibco BRL) or 20% allo-
geneic serum from healthy control subjects, patients with JIA,
or patients with childhood-onset SLE. The media was changed
every 3 days. After 14 days, differentiation into mature
ECs was quantified by assessing coexpression of Texas red–
conjugated acetylated low-density lipoprotein (Biomedical
Technologies) and fluorescein isothiocyanate–conjugated Ulex
europaeus agglutinin type I (Vector) by fluorescence micros-
copy (Leica DMIRB inverted microscope) using Cell C cell-
counting software (12). Seven photomicrographs were
obtained per field, with results reported as the mean6 SEM
per sample. For studies using allogeneic human serum, cells
were cultured in the presence or absence of 2 mg/ml neutraliz-
ing anti-human interferon a/b (IFNa/b) receptor (PBL Bio-
medical) or IgG2a isotype (Abcam). Antibody was added at
each media change every 2–3 days, and cells were quantified as
described above.
Serum type I IFN activity. This bioassay has been
described elsewhere (13). Briefly, HeLa cells were incubated
with Dulbecco’s modified Eagle’s medium/10% FBS (negative
control), 1 Kunit/well recombinant IFNa (Invitrogen) as posi-
tive control, 50% SLE sera (by volume), or 50% control sera
for 6 hours. RNA was extracted using RNeasy (Qiagen) and
reverse transcribed to complementary DNA (Invitrogen).
Real-time polymerase chain reaction was performed in tripli-
cate on an ABI Prism 7900HT system (Applied Biosystems)
using 23 SYBR Green Supermix (Bio-Rad), to quantify the
following 5 type I IFN-inducible genes (IFIGs): myxovirus
resistance protein 1 (MX1), double-stranded RNA activated
protein kinase (PRKR), IFN-induced protein with tetratrico-
peptide repeats (IFIT1), IFN-induced protein 44 (IFI44), and
IFN-induced protein 44-like (C1orf29); the housekeeping gene
hypoxanthine guanine phosphoribosyltransferase 1 (HPRT1)
was also quantified. Primers were obtained from Integrated
DNA Technologies. The results of quantification were aver-
aged, normalized to the housekeeping gene, and plotted as the
fold induction relative to 25 age- and sex-matched healthy con-
trol subjects.
Statistical analysis. Multivariable linear regression
analyses were performed to determine associations between
individual IFIGs and vascular markers (CIMT, FMD, and
PWV), adjusting for age, sex, and medications. A principal
components analysis was applied to assess for differences in
the profiles of IFIGs as compared with vascular measures, as
described for adult-onset SLE (13). Differences in mean values
for EPC quantification and differentiation were analyzed using
Student’s t-test. Clinical data were adjusted for disease activity.
To examine associations between clinical and demographic var-
iables and vascular dysfunction, a Mann-Whitney test compar-
ing medians was used for categorical data, because outcomes
were not normally distributed, and simple linear regression was
used for continuous variables. Differences in the demographic
data of the cohorts were assessed for significance using chi-
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square or Fisher’s exact tests for categorical variables and one-
way analysis of variance for continuous variables.
RESULTS
Patient characteristics. The demographic and
clinical characteristics of the patients with childhood-
onset SLE, the patients with JIA, and the healthy control
subjects are shown in Table 1. Patients at HSC were
younger than patients at UM, because the minimum ages
at the time of enrollment were 9 years and 12 years,
respectively, due to the large volume of blood needed for
EPC experiments. Disease duration was longer in the
UM patients compared with the HSC patients. The mean
disease duration was longer in the UM patients with
childhood-onset SLE compared with the HSC patients
with childhood-onset SLE, and in the UM cohort of
patients with JIA, disease was more long-standing at the
time of enrollment than in patients with childhood-onset
SLE. Most patients with childhood-onset SLE were
receiving hydroxychloroquine, half were receiving a
steroid-sparing agent, and most of those receiving predni-
sone were receiving,0.5 mg/kg daily.
Vascular testing. The mean6 SEM CIMT in
healthy controls was 0.4396 0.045 mm and was signifi-
cantly higher that in patients with childhood-onset SLE
(0.4106 0.050 mm; P, 0.001). FMD values were higher
in patients with childhood-onset SLE compared with
healthy control subjects (mean6 SEM 8.26 3.9% versus
7.56 3.2%), but the difference was not statistically
significant (P5 0.808). PWV values assessing arterial
stiffness did not differ between patients with childhood-
onset SLE and healthy control subjects (mean6SEM
5.46 1.0 mm/second versus 5.16 0.9 mm/second;
P5 0.328) (Table 1). Less than 2% of patients with
childhood-onset SLE undergoing vascular testing had
results that deviated .2 SD from those in healthy con-
trol subjects (for CIMT, for 4 of 127 SLE patients; for
PWV, for 4 of 126 SLE patients; for FMD, for 0 of 127
SLE patients). As such, the baseline data of the
childhood-onset SLE cohort did not suggest significant
vascular dysfunction in these patients.
Effect of type I IFNs on phenotype and function
of EPCs in patients with childhood-onset SLE. The
number of circulating EPCs was significantly decreased
Table 1. Demographic and clinical characteristics of the study subjects*
Hospital for Sick Children University of Michigan
Childhood-
onset SLE
(n5 132)
Healthy
controls
(n5 178)
Childhood-
onset SLE
(n5 25)
JIA
(n5 21)
Healthy
controls
(n5 29) P†
Age, mean6 SEM years 14.86 2.7 14.46 2.1 18.26 2.7 15.46 2.3 14.56 4.7 ,0.001‡
No. male/no. female 23/109 84/94 3/22 8/13 8/21 0.078§
Disease duration, mean6 SEM years 2.16 2.1 NA 4.06 3.0 6.06 5.4 NA ,0.01¶
Disease duration range, years 0.2213.3 NA 029.0 0215.0 NA –
Current medications
NSAIDs 14 (11) – 10 (40) 16 (76) – ,0.001
ACE inhibitors or ARBs 25 (19) – 15 (60) None – ,0.001
Prednisone 82 (62) – 13 (52) 1 (5) – 0.377
Hydroxychloroquine 114 (86) – 24 (96) 12 (57) – 0.008
Mycophenolate 24 (18) – 11 (44) None – 0.008
Azathioprine 42 (32) – 3 (12) None – 0.054
Cyclophosphamide 17 (13) – 1 (4) None – 0.312
Methotrexate 7 (5) – 1 (4) 5 (24) – 0.008
Cyclosporine 3 (2) – 2 (8) 1 (5) – 0.323
IVIG 4 (3) – 0 (0) None – 1
Vascular markers
CIMT, mean6 SEM mm 0.4106 0.050 0.4396 0.045 – – – ,0.001
FMD, mean6 SEM % change 8.26 3.9 7.56 3.2 – – – 0.808
PWV, mean6 SEM mm/second 5.46 1.0 5.16 0.9 – – – 0.328
* Medications that are used primarily to treat systemic lupus erythematosus (SLE) were compared only between the 2 cohorts of patients with
childhood-onset SLE, because these medications are not used to treat juvenile idiopathic arthritis (JIA). Except where indicated otherwise, val-
ues are the number (%). NA5 not applicable; NSAIDs5 nonsteroidal antiinflammatory drugs; ACE5 angiotensin-converting enzyme;
ARBs5 angiotensin II receptor blockers; IVIG5 intravenous immunoglobulin; CIMT5 carotid intima-media thickness; FMD5 flow-mediated
dilation; PWV5pulse wave velocity.
† By one-way analysis of variance for multiple comparisons of continuous variables and chi-square or Fisher’s exact test for multiple comparisons
of categorical variables.
‡ Hospital for Sick Children SLE patients versus University of Michigan SLE patients; other age differences were not significant.
§ By chi-square test.
¶ Hospital for Sick Children SLE patients versus University of Michigan SLE patients.
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in patients with childhood-onset SLE compared with the
numbers in healthy control subjects and patients with JIA
(Figure 1A), and no correlation with age (P5 0.391), dis-
ease duration (P5 0.692), or immunosuppressive medica-
tions (for mycophenolate, P5 0.062; for prednisone,
P5 0.442) was observed. In comparison with EPCs from
healthy control subjects or patients with JIA, EPCs from
patients with childhood-onset SLE displayed a signifi-
cantly decreased capacity to differentiate into mature ECs
(P5 0.01) (Figure 1B). Increasing age appeared to be
associated with decreased differentiation, as determined
by linear regression analysis (P5 0.034), while disease
duration was not associated with decreased differentia-
tion (P5 0.242). There was no association between treat-
ment with mycophenolate or azathioprine and the
number or function of EPCs (P5 0.399 and P5 0.167,
respectively) when comparing patients receiving these
drugs and those not receiving these drugs. Insufficient
numbers of patients were receiving high-dose prednisone
($1 mg/kg/day) or cyclophosphamide to allow testing for
changes in EPC function. There was no correlation
between EPC levels in patients with childhood-onset SLE
and the Systemic Lupus Erythematosus Disease Activity
Index (18), body mass index (BMI), systolic blood pres-
sure, the creatinine level, the erythrocyte sedimentation
rate (ESR) the C-reactive protein (CRP) level, or the
lipid profile (P. 0.05).
To assess the role of circulating type I IFNs in
inhibiting EC differentiation in patients with childhood-
onset SLE, EPCs obtained from healthy control subjects
were differentiated into mature ECs in 20% allogeneic
serum from healthy control subjects, patients with JIA,
and patients with childhood-onset SLE, under proangio-
genic stimulation (Figure 2A), as previously described
(12). Serum from patients with childhood-onset SLE,
but not that from patients with JIA, significantly ham-
pered EC differentiation when compared with serum
from healthy control subjects (P , 0.01) (Figure 2B).
The detrimental effect of serum from patients with
childhood-onset SLE on EC differentiation was signifi-
cantly attenuated by neutralizing antibodies to IFNa/b
receptor (P, 0.05) (Figure 2C). Neutralizing antibodies
to IFNa/b receptor had no significant effect on control
EPCs that were exposed to serum from patients with JIA
or serum from healthy control subjects.
Type I IFN signatures and vascular assess-
ments in childhood-onset SLE. Serum type I IFN activ-
ity was significantly increased in patients with childhood-
onset SLE (additional information is available from the
corresponding author). Serum IFN activity did not cor-
relate with the body mass index, systolic blood pressure,
the creatinine level, the CRP level, the ESR, or lipid pro-
files. Post hoc analysis showed a trend toward an associa-
tion between higher expression of the IFN-inducible
genes PRKR and C1orf29 in those patients with
childhood-onset SLE who had CIMT values that devi-
ated.1 SD from the mean values in healthy control sub-
jects (P5 0.053 and P5 0.074, respectively).
DISCUSSION
Type I IFNs appear to play important roles in
SLE pathogenesis and in the accelerated atherosclerosis
characteristic of this disease (8,9,11–13). In adult-onset
Figure 1. Numbers and differentiation of endothelial progenitor cells (EPCs) in healthy control subjects, patients with juvenile idiopathic arthri-
tis (JIA), and patients with childhood-onset systemic lupus erythematosus (SLE). A, Numbers of EPCs in the circulating blood of healthy control
subjects (n5 14), patients with JIA (n5 9), and patients with childhood-onset SLE (n5 19). B, EPC differentiation in healthy control subjects,
patients with JIA, and patients with childhood-onset SLE, as assessed by fluorescence microscopy (n5 12 per group). Coexpression of Texas
Red–conjugated acetylated low-density lipoprotein and fluorescein isothiocyanate–conjugated Ulex europaeus agglutinin type I identified mature
ECs. Values are the mean6 SEM. hpf5 high-power field; NS5 not significant. *5P , 0.05 versus control and JIA.
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SLE, type I IFN activity has been linked to decreased vas-
cular function, higher CIMT, and coronary calcification
(13). Murine and human studies have shown that type I
IFNs have significant pleiotropic effects that are deleteri-
ous to the vasculature, including the promotion of endo-
thelial damage, impairment of endothelial repair,
facilitation of foam cell formation, and enhancement of
thrombosis (11,12). Indeed, type I IFNs are directly cyto-
toxic to EPCs and impair their function (7,10,14).
It is well recognized that childhood-onset SLE is
associated with an elevated type I IFN signature (9); how-
ever, it is unknown whether children are equally suscepti-
ble to EPC impairment and accelerated vascular damage
by type I IFNs. Decreased numbers of EPCs and impaired
endothelial function have been described in other pediat-
ric autoimmune diseases, such as type 1 diabetes mellitus
(15), and obese children display decreased numbers of
circulating EPCs in association with vascular dysfunction
(14). We observed decreased numbers and function of cir-
culating EPCs from patients with childhood-onset SLE,
similar to what we and other investigators observed in
adult-onset SLE. Increasing age was the only variable that
significantly correlated with reduced EPC differentiation.
Immunosuppression did not appear to impact EPC differ-
entiation, although too few patients were receiving high-
dose prednisone or cyclophosphamide to allow analysis of
these contributions.
Previous studies in patients with adult-onset SLE
showed that IFIGs were associated with decreased endo-
thelial function, increased CIMT, arterial stiffness, and
the severity of coronary calcification (13). We could not
confirm these observations in patients with childhood-
onset SLE, even though the levels of type I IFNs were
increased in these patients compared with healthy con-
trols, and CIMT was in fact lower in patients with
childhood-onset SLE compared with healthy controls.
The lack of significant differences in vascular measure-
ments between patients with childhood-onset SLE and
healthy controls is likely a main factor in the lack of cor-
relation with type I IFNs. Indeed, only a minority of
Figure 2. Role of circulating interferon-a (IFNa) on EPCs in childhood-onset SLE. A, Representative photomicrographs of EPCs from healthy
control (HC) subjects cultured for 14 days in 20% sera from healthy control subjects (n5 5), patients with JIA (n5 5), and patients with
childhood-onset SLE (n5 7). Cells were labeled with DiI-labeled acetylated low-density lipoprotein (red) and fluorescein isothiocyanate–conju-
gated Ulex europaeus agglutinin type I (green). Mature endothelial cells coexpressed both markers (yellow). Original magnification 3 10. B,
Effect of sera from healthy control subjects, patients with JIA, and patients with childhood-onset SLE on the survival of healthy EPCs on day 15.
**5P , 0.01 versus control, by one-way analysis of variance followed by Dunnett’s multiple comparison test. C, Effect of IFNa signaling blockade
on EC differentiation in control cells exposed to sera from healthy control subjects, patients with JIA, and patients with SLE. *5P , 0.05, by
paired t-test. Values in B and C are the mean6 SEM. See Figure 1 for other definitions.
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patients with childhood-onset SLE had abnormal values,
unlike those observed in the study of adult patients. Fur-
thermore, a post hoc exploratory analysis showed a trend
toward an association of specific IFIGs and higher
CIMT values. The significance of these findings needs to
be confirmed in an independent cohort in which more
subjects have abnormal values. As such, the differences
between the adult and pediatric SLE studies regarding
associations between type I IFN responses and functional/
anatomic evidence of cardiovascular disease (CVD) are
likely related to a lack of prominent vascular damage
in this cohort of patients with childhood-onset SLE.
Longer followup will be needed to assess the role of
these cytokines in the progression of CVD in childhood-
onset SLE.
The results of this study suggest that, similar to
adult-onset SLE, childhood-onset SLE is characterized by
impaired EPC phenotype and function, which are likely
driven by type I IFNs. Future longitudinal studies should
systematically assess whether these abnormalities contrib-
ute to the severity and/or progression of premature vascu-
lar damage and CV events in childhood-onset SLE.
ACKNOWLEDGMENTS
We thank the University of Michigan Center for Statis-
tical Consultation and Research for assistance with statistical
analysis and Keri Gisslen for assistance with recruitment.
AUTHOR CONTRIBUTIONS
All authors were involved in drafting the article or revising it
critically for important intellectual content, and all authors approved
the final version to be published. Dr. Kaplan had full access to all of the
data in the study and takes responsibility for the integrity of the data
and the accuracy of the data analysis.
Study conception and design. Barsalou, Bradley, Kaplan.
Acquisition of data. Mohan, Barsalou, Bradley, Slorach, Reynolds,
Hasni, Thompson, Ng, Levy, Silverman.
Analysis and interpretation of data. Mohan, Barsalou, Bradley,
Slorach, Reynolds, Silverman, Kaplan.
REFERENCES
1. Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C,
du Berger R, et al. Traditional Framingham risk factors fail to
fully account for accelerated atherosclerosis in systemic lupus
erythematosus. Arthritis Rheum 2001;44:2331–7.
2. Kaplan MJ. Premature vascular damage in systemic lupus ery-
thematosus. Autoimmunity 2009;42:580–6.
3. Stichweh D, Arce E, Pascual V. Update on pediatric systemic
lupus erythematosus. Curr Opin Rheumatol 2004;16:577–87.
4. Urbina EM, Williams RV, Alpert BS, Collins RT, Daniels SR,
Hayman L, et al. Noninvasive assessment of subclinical athero-
sclerosis in children and adolescents: recommendations for stand-
ard assessment for clinical research: a scientific statement from
the American Heart Association. Hypertension 2009;54:919–50.
5. Barsalou J, Bradley TJ, Silverman ED. Cardiovascular risk in
pediatric-onset rheumatological diseases. Arthritis Res Ther
2013;15:212.
6. Ardoin SP, Schanberg LE, Sandborg CI, Barnhart HX, Evans
GW, Yow E, et al. Secondary analysis of APPLE study suggests
atorvastatin may reduce atherosclerosis progression in pubertal
lupus patients with higher C reactive protein. Ann Rheum Dis
2014;73:557–66.
7. Rajagopalan S, Somers EC, Brook RD, Kehrer C, Pfenninger D,
Lewis E, et al. Endothelial cell apoptosis in systemic lupus ery-
thematosus: a common pathway for abnormal vascular function
and thrombosis propensity. Blood 2004;103:3677–83.
8. Denny M, Thacker S, Mehta H, Somers EC, Dodick T, Barrat
FJ, et al. Interferon-a promotes abnormal vasculogenesis in
lupus: a potential pathway for premature atherosclerosis. Blood
2007;110:2907–15.
9. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak K,
Banchereau J, et al. Interferon and granulopoiesis signatures in
systemic lupus erythematosus blood. J Exp Med 2003;197:711–23.
10. Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A,
et al. Circulating endothelial progenitor cells and cardiovascular
outcomes. N Engl J Med 2005;353:999–1007.
11. Thacker S, Zhao W, Smith C, Luo W, Wang H, Vivekanandan-
Giri A, et al. Type I interferons modulate endothelial function,
repair, thrombosis and plaque severity in murine models of
lupus and atherosclerosis. Arthritis Rheum 2012;64:2975–85.
12. Thacker S, Berthier C, Mattinzoli D, Rastaldi MP, Kretzler M,
Kaplan MJ. The detrimental effects of interferon-a on vasculo-
genesis in lupus are mediated by repression of IL-1 pathways:
potential role in atherogenesis and renal vascular rarefaction.
J Immunology 2010;185:4457–69.
13. Somers EC, Zhao W, Lewis EE, Wang L, Wing JJ, Sundaram
B, et al. Type I interferons are associated with subclinical
markers of cardiovascular disease in a cohort of systemic lupus
erythematosus patients. PLoS One 2012;7:e37000.
14. Bruyndonckx L, Hoymans VY, Frederix G, De Guchtenaere A,
Franckx H, Vissers DK, et al. Endothelial progenitor cells and
endothelial microparticles are independent predictors of endo-
thelial function. J Pediatr 2014;165:300–5.
15. Hortenhuber T, Rami-Mehar B, Satler M, Nagl K, Hobaus C,
Hollerl F, et al. Endothelial progenitor cells are related to glyce-
mic control in children with type 1 diabetes over time. Diabetes
Care 2013;36:1647–53.
16. Hochberg MC, for the Diagnostic and Therapeutic Criteria
Committee of the American College of Rheumatology. Updating
the American College of Rheumatology revised criteria for the
classification of systemic lupus erythematosus [letter]. Arthritis
Rheum 1997;40:1725.
17. Petty RE, Southwood TR, Baum J, Bhettay E, Glass DN,
Manners P, et al. Revision of the proposed classification criteria
for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol
1998;25:1991–4.
18. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang
DH, and the Committee on Prognosis Studies in SLE. Deriva-
tion of the SLEDAI: a disease activity index for lupus patients.
Arthritis Rheum 1992;35:630–40.
2262 MOHAN ET AL
